Neurocrine Biosciences
CA · 19 filings, 2025
What the money shows
Neurocrine Biosciences reported $3.6M in federal lobbying for 2025 across 19 filings. The filings name 5 lobbying firms, led by BGR Government Affairs and LMH Strategic Solutions. The filing text lists 5 issue areas.
Sources: Senate LDA · FEC
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD). via Wikipedia ↗
1Lobbies on
Its filings list: Medicare/Medicaid · Health Issues · Budget/Appropriations · Pharmacy · Taxation/Internal Revenue Code
2Through these firms · 5
3Bills moving in its lanes
No bill names this company outright; these are recent bills in the sectors it lobbies.
- S 5236A bill to amend title XIX of the Social Security Act to ensure Medicaid coverage of mental health services…
- S 5225A bill to amend the Elementary and Secondary Education Act of 1965 to include certain curriculum expenses a…
- S 5227A bill to amend the Internal Revenue Code of 1986 to allow certain distributions from long-term qualified t…
- S 5232A bill to amend the Public Health Service Act to authorize rural residency planning and development grant p…
- S 5237A bill to require the Director of the National Institute of Allergy and Infectious Diseases to award a comp…